Analysis of Risk Factors of Pneumonia Caused by Thee Novel Coronavirus

LI Jing’e; WANG Furong; CHAI Jun; YAO Lili; TIAN Guangyuan; GAO Xiaoyu; SUN Dejun

doi:10.15953/j.ctta.2023.057

Volume 32 Issue 3

May 2023

Turn off MathJax

Article Contents

Abstract

References

CT Theory and Applications > 2023 > 32(3): 419-427. > DOI: 10.15953/j.ctta.2023.057

LI J, WANG F R, CHAI J, et al. Analysis of Risk Factors of Pneumonia Caused by Thee Novel Coronavirus[J]. CT Theory and Applications, 2023, 32(3): 419-427. DOI: 10.15953/j.ctta.2023.057. (in Chinese).

Citation:

PDF (1865 KB)

Analysis of Risk Factors of Pneumonia Caused by Thee Novel Coronavirus

LI Jing’e^{1, 2, 3a,},
WANG Furong⁴,
CHAI Jun^3b,
YAO Lili^3a,
TIAN Guangyuan²,
GAO Xiaoyu²,
SUN Dejun^{2, 3a, ,}

1.
Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014000, China
2.
Key Laboratory of COPD Diagnosis and Treatment of National Health Commission, Inner Mongolia Autonomous Region People's Hospital/Inner Mongolia Key Laboratory of Respiratory Diseases, Hohhot 010017, China
1.
Inner Mongolia People's Hospital, Hohhot 010017, China Department of Respiratory and Critical Care Medicine
2.
Inner Mongolia People's Hospital, Hohhot 010017, China Department of Imaging Medicine
4.
The Fourth Hospital of Inner Mongolia Autonomous Region, Hohhot 010010, China

More Information

Received Date: March 13, 2023
Revised Date: April 12, 2023
Accepted Date: April 16, 2023
Available Online: May 03, 2023
Published Date: May 30, 2023

Graphical Abstract

Abstract

Abstract

Objective: To analyze the risk factors associated with the development of coronavirus disease 2019 (COVID-19) and enhance the understanding of its disease progression, providing a clinical basis for diagnosis, treatment, and prevention of severe diseases. Methods: A retrospective analysis of 399 patients with COVID-19 was conducted at a designated hospital for COVID-19 treatment in Inner Mongolia Autonomous Region, focusing on the characteristics and risk factors associated with the development of COVID-19. Univariate and binary logistic regression analyses were used to explore the risk factors for novel coronavirus infection. Results: There were significant differences in age, underlying disease history, laboratory examination, and clinical symptoms between the two groups. Univariate analysis showed significant differences in age, diabetes, rheumatoid arthritis, albumin concentration, albumin/globulin ratio, and IL-6 and C-reactive protein levels between the two groups. Binary Logistic regression analysis showed that C-reactive protein level, endocrine disease history, and ORF1ab gene CT value may be risk factors for COVID-19, whereas albumin level may be a protective factor. Conclusion: Age, underlying disease history, and elevated C-reactive protein/IL-6 levels are contributing factors to the development of COVID-19. Further targeted preventive interventions should consider the risk factors of the disease.
- novel coronavirus infectious pneumonia,
- risk factors,
- Omicron

FullText(HTML)

References (45)

References

[1]	ZHOU F, YU T, DU R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054−1062. doi: 10.1016/S0140-6736(20)30566-3
[2]	ALEEM A, AKBAR SAMAD A B, SLENKER A K. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)[M]. StatPearls. Treasure Island (FL); StatPearls Publishing Copyright 2022, StatPearls Publishing LLC. 2022.
[3]	葛玲玲, 董旭, 王歆妤, 等. 奥密克戎BA.2变异株感染者不同部位样本核酸阴转时间及影响因素分析[J]. 海军军医大学学报, 2022,43(11): 1240−1246.
[4]	ZHANG H, CHEN W, YE X, et al. Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and Omicron variant strain in Quanzhou: A real‑world study[J]. Experimental and Therapeutic Medicine, 2023, 25(1): 62.
[5]	CALLAWAY E. What Omicron's BA.4 and BA.5 variants mean for the pandemic[J]. Nature, 2022, 606(7916): 848−849. doi: 10.1038/d41586-022-01730-y
[6]	BRüSSOW H. COVID-19: Omicron-the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2[J]. Microbial Biotechnology, 2022, 15(7): 1927−1939. doi: 10.1111/1751-7915.14064
[7]	CHATTERJEE S, BHATTACHARYA M, NAG S, et al. A detailed overview of SARS-CoV-2 Omicron: Its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies[J]. Viruses, 2023, 15(1).
[8]	YING W F, CHEN Q, JIANG Z K, et al. Chest computed tomography findings of the Omicron variants of SARS-CoV-2 with different cycle threshold values[J]. World Journal of Clinical Cases, 2023, 11(4): 756−763. doi: 10.12998/wjcc.v11.i4.756
[9]	SHA J, MENG C, SUN J, et al. Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China[J]. Journal of Infection and Public Health, 2023, 16(3): 422−429. doi: 10.1016/j.jiph.2023.01.013
[10]	中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国医药, 2022,17(4): 481−487.
[11]	FLOOK M, JACKSON C, VASILEIOU E, et al. Informing the public health response to COVID-19: A systematic review of risk factors for disease, severity, and mortality[J]. BMC Infectious Diseases, 2021, 21(1): 342. doi: 10.1186/s12879-021-05992-1
[12]	SHAW A C, JOSHI S, GREENWOOD H, et al. Aging of the innate immune system[J]. Current Opinion in Immunology, 2010, 22(4): 507−513. doi: 10.1016/j.coi.2010.05.003
[13]	GAO Y D, DING M, DONG X, et al. Risk factors for severe and critically ill COVID-19 patients: A review[J]. Allergy, 2021, 76(2): 428−455. doi: 10.1111/all.14657
[14]	BREZNIK J A, RAHIM A, KAJAKS T, et al. Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada[J]. Journal of the American Medical Directors Association, 2023.
[15]	WU J T, LEUNG K, BUSHMAN M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China[J]. Nature Medicine, 2020, 26(4): 506−510. doi: 10.1038/s41591-020-0822-7
[16]	喻博识, 陈文娟, 陈小慧, 等. ACE2、TMPRSS2表达与小鼠COVID-19易感年龄及潜在靶器官关系的探讨[J]. 安徽医科大学学报, 2021,56(6): 986−990. doi: 10.19405/j.cnki.issn1000-1492.2021.06.030 YU B S, CHEN W J, CHEN X H, et al. Study on the relationship between the expression of ACE2 and TMPRSS2 and the susceptible age and potential target organs of COVID-19 in mice[J]. Acta Universitatis Medicinalis Anhui, 2021, 56(6): 986−990. (in Chinese). doi: 10.19405/j.cnki.issn1000-1492.2021.06.030
[17]	WANG M, MI H, LI N, et al. Association between the overall burden of comorbidity and CT values among the older patients with Omicron infection: Mediated by inflammation[J]. Frontiers in Immunology, 2023, 14: 1145044. doi: 10.3389/fimmu.2023.1145044
[18]	GUAN W J, LIANG W H, ZHAO Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis[J]. The European Respiratory Journal, 2020, 55(5): 2000547.
[19]	IZZI-ENGBEAYA C, DISTASO W, AMIN A, et al. Adverse outcomes in COVID-19 and diabetes: A retrospective cohort study from three London teaching hospitals[J]. BMJ Open Diabetes Research & Care, 2021, 9(1): 001858.
[20]	TSAMPASIAN V, ELGHAZALY H, CHATTOPADHYAY R, et al. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis[J]. JAMA Internal Medicine, 2023: e230750.
[21]	BASTARD P, ROSEN L B, ZHANG Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19[J]. Science, 2020, 370(6515).
[22]	TRIMBOLI P, CAMPONOVO C, SCAPPATICCIO L, et al. Thyroid sequelae of COVID-19: A systematic review of reviews[J]. Reviews in Endocrine & Metabolic Disorders, 2021, 22(2): 485−491.
[23]	OU M, ZHU J, JI P, et al. Risk factors of severe cases with COVID-19: A meta-analysis[J]. Epidemiology and Infection, 2020, 148: e175. doi: 10.1017/S095026882000179X
[24]	DU H, DONG X, ZHANG J J, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status[J]. Allergy, 2021, 76(2): 510−532. doi: 10.1111/all.14452
[25]	FLOYD J S, WALKER R L, KUNTZ J L, et al. Association between diabetes severity and risks of COVID-19 infection and outcomes[J]. Journal of General Internal Medicine, 2023: 1−9.
[26]	杨烨坤, 钱捷. 新型冠状病毒肺炎与类风湿关节炎的研究进展[J]. 实用临床医药杂志, 2021,25(23): 115−123.
[27]	EL-SABER BATIHA G, AL-GAREEB A I, SAAD H M, et al. COVID-19 and corticosteroids: A narrative review[J]. Inflammopharmacology, 2022, 30(4): 1189−1205. doi: 10.1007/s10787-022-00987-z
[28]	RAJPAL A, RAHIMI L, ISMAIL-BEIGI F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes[J]. Journal of Diabetes, 2020, 12(12): 895−908. doi: 10.1111/1753-0407.13085
[29]	HAYDEN M R. Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019[J]. The Journal of International Medical Research, 2020, 48(7): 300060520939746.
[30]	ABUMWEIS S, ALREFAI W, ALZOUGHOOL F. Association of obesity with COVID-19 diseases severity and mortality: A meta-analysis of studies[J]. Obesity Medicine, 2022, 33: 100431. doi: 10.1016/j.obmed.2022.100431
[31]	KHAN M S, SHAHID I, ANKER S D, et al. Cardiovascular implications of COVID-19 versus influenza infection: A review[J]. BMC Medicine, 2020, 18(1): 403. doi: 10.1186/s12916-020-01816-2
[32]	BRAR G, PINHEIRO L C, SHUSTERMAN M, et al. COVID-19 severity and outcomes in patients with cancer: A matched cohort study[J]. Journal of Clinical Oncology, 2020, 38(33): 3914−3924. doi: 10.1200/JCO.20.01580
[33]	CHEN S, SUN H, HENG M, et al. Factors predicting progression to severe COVID-19: A competing risk survival analysis of 1753 patients in community isolation in Wuhan, China[J]. Engineering, 2022, 13: 99−106.
[34]	SOKOLOWSKA M, LUKASIK Z M, AGACHE I, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives: A report of the European Academy of Allergy and Clinical Immunology (EAACI)[J]. Allergy, 2020, 75(10): 2445−2476. doi: 10.1111/all.14462
[35]	HENRY B M, de OLIVEIRA M H S, BENOIT S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis[J]. Clinical Chemistry and Laboratory Medicine, 2020, 58(7): 1021−1028. doi: 10.1515/cclm-2020-0369
[36]	CHEN X, ZHAO B, QU Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019[J]. Clinical Infectious Diseases, 2020, 71(8): 1937−1942. doi: 10.1093/cid/ciaa449
[37]	ZHANG J J, CAO Y Y, TAN G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients[J]. Allergy, 2021, 76(2): 533−550. doi: 10.1111/all.14496
[38]	AZKUR A K, AKDIS M, AZKUR D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19[J]. Allergy, 2020, 75(7): 1564−1581. doi: 10.1111/all.14364
[39]	DANWANG C, ENDOMBA F T, NKECK J R, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)[J]. Biomarker Research, 2020, 8: 37. doi: 10.1186/s40364-020-00217-0
[40]	YU Q, WANG Y, HUANG S, et al. Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients[J]. Theranostics, 2020, 10(12): 5641−5648. doi: 10.7150/thno.46465
[41]	AHMED J, RIZWAN T, MALIK F, et al. COVID-19 and liver injury: A systematic review and Meta-analysis[J]. Cureus, 2020, 12(7): e9424.
[42]	KOVALIC A J, HUANG G, THULUVATH P J, et al. Elevated liver biochemistries in hospitalized Chinese patients with severe COVID-19: Systematic review and meta-analysis[J]. Hepatology (Baltimore, Md), 2021, 73(4): 1521−1530. doi: 10.1002/hep.31472
[43]	YE L, CHEN B, WANG Y, et al. Prognostic value of liver biochemical parameters for COVID-19 mortality[J]. Annals of Hepatology, 2021, 21: 100279. doi: 10.1016/j.aohep.2020.10.007
[44]	RAO S N, MANISSERO D, STEELE V R, et al. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19[J]. Infectious Diseases and Therapy, 2020, 9(3): 573−586. doi: 10.1007/s40121-020-00324-3
[45]	CAO S, GAN Y, WANG C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China[J]. Nature Communications, 2020, 11(1): 5917. doi: 10.1038/s41467-020-19802-w

Cited By

Cited by

Periodical cited type(2)

1.	张科，张春晓. 基于深度残差网络的儿科肺炎辅助诊断算法. 中国医疗设备. 2022(09): 42-46+56 .
2.	周丽媛，赵启军，高定国. 基于注意力引导深度纹理特征学习的复杂背景藏药材切片图像识别. 世界科学技术-中医药现代化. 2022(12): 4825-4832 .

Other cited types(5)

Get Citation

PDF

XML

Article views (277) PDF downloads (26) Cited by(7)

Analysis of Risk Factors of Pneumonia Caused by Thee Novel Coronavirus

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(5)

Catalog

Related

Analysis of Risk Factors of Pneumonia Caused by Thee Novel Coronavirus

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(5)

Catalog

Related

Export File

Citation

Format

Content